FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Italy Fines Apple €98.6 Million Over App Store Dominance 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
ATLANTA, March 23, 2016 -- Femasys Inc., a developer of innovative medical devices for the women's healthcare market today announced that Fred Aslan, Founder and Chief Executive Officer of Advance Medical, Inc. and Vice President of Venrock and Charles E. Larsen, Managing Director of Accuitive Medical Ventures, have been appointed to the Femasys Board of Directors. Both new directors bring significant leadership, operations and commercial experience to Femasys as the Company prepares to commence its pivotal trial of FemBlocTM which is designed to provide women with the first non-surgical permanent contraception option delivered exclusively in the office.
"We are extremely honored to have Fred and Charlie join our Board of Directors – they are proven executives who have been successful starting new businesses, developing and commercializing emerging technologies, building organizations and delivering value to shareholders,” said Kathy Lee-Sepsick, President and CEO of Femasys. “Their considerable experience will be invaluable to our team as we embark on the next phase of development with FemBlocTM.”
Dr. Aslan has over 15 years of strategic management and direct investment experience in the medical device, diagnostics, and biotechnology sectors. Dr. Aslan is currently the Founder and Chief Executive Officer of Advance Medical, a Venrock portfolio company that is focused on the commercialization of medical device and diagnostics technologies in Brazil, and he is also a Vice President at Venrock. Dr. Aslan has served on the Board of Directors of Receptos, a company recently acquired by Celgene, and has been a Board observer for a number of other companies including Zeltiq and PowerVision. Dr. Aslan was the Director of Business Development and Investor Relations at CuraGen Corporation. Prior to CuraGen, he worked at Boston Consulting Group where he advised biotechnology and pharmaceutical companies on a number of strategic initiatives. Dr. Aslan received his B.S. in Biology from Duke University, M.D. from Yale University School of Medicine and M.B.A. from the Harvard Business School.
Mr. Larsen has over 35 years of operating and technical experience in the medical device industry. He co-founded Novoste Corporation and The Innovation Factory and through his role at The Innovation Factory, he co-founded additional companies including: Acufocus, AqueSys, Halscion, LipoSonix, Neuronetics and Sebacia. He holds over 30 issued U.S. and international patents on medical devices. Before joining Novoste, Mr. Larsen held positions with Novoste Puerto Rico, Cordis Corporation, Key Pharmaceuticals and Parke-Davis/Warner Lambert in executive, senior engineering and project management roles. Mr. Larsen received a B.S. in Mechanical Engineering from the New Jersey Institute of Technology. Mr. Larsen currently is member of the Board of Directors for Acufocus, CardioFocus, Intuity, and Torax.
ABOUT FEMASYS INC.
Femasys Inc., based in Atlanta, GA, is a privately held corporation committed to transforming women's healthcare worldwide by expanding options for women with innovative medical devices and next generation advancements providing significant clinical impact. Additional information about Femasys and the Company’s products can be found at www.femasys.com
Femasys has developed a groundbreaking non-surgical female sterilization device (FemBloc™ Permanent Contraceptive System) that allows physicians to deliver exclusively in their office a Biopolymer through a catheter-based Delivery System to permanently block the fallopian tubes in a procedure that substantially reduces patient risks and costs by eliminating the use of anesthesia and permanent implants. The company has also expanded options for women with its two commercially available products for diagnosis of infertility (FemVue® Saline-Air device) and cervical cancer (FemCerv® Endocervical Sampler) that present significant advantages for the patient, physician, and healthcare system.
Femasys, FemBloc, FemVue and FemCerv are registered trademarks of Femasys Inc. All rights reserved.
Femasys Media Contact Jerry Fink 770.500.3910 x-132 [email protected]
